Carcinoma, Renal Cell Clinical Trial
Official title:
A Multi-Center, Phase 2, Open Label Study of Safety and Efficacy of Oral Recombinant Human Lactoferrin (rhLF) Monotherapy in Patients With Advanced Renal Cell Carcinoma (RCC), Who Have Failed at Least One Regimen of Systemic Therapy for RCC
Verified date | April 2008 |
Source | Agennix |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine if orally-administered recombinant human lactoferrin is effective in the treatment of advanced renal cell carcinoma (RCC) in patients who have failed at least one prior systemic therapy for RCC.
Status | Completed |
Enrollment | 40 |
Est. completion date | March 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age =18 years - Histologically confirmed, advanced or metastatic RCC with predominantly clear cell histology that is unresectable or medically inoperable. - Experienced and failed at least one regimen of systemic therapy for RCC with CT documentation of disease progression. - A previous CT (4 weeks or more prior to the Screening CT) showing progression of the target tumor(s) compared to a prior CT no more than 9 months previously - At least one target tumor lesion is measurable at Screening with CT scan, according to RECIST, and not previously irradiated - Karnofsky performance status of =70 (ECOG <2) - Able to understand and sign an informed consent Exclusion Criteria: - Significant sarcomatoid, spindle cell, or nuclear grade 4 histology - Significant non-clear cell RCC (for example, papillary, chromophobe, collecting duct, granular, or unclassified RCC) - Total bilirubin >1.5 mg/dL - Serum creatinine >2.0 mg/dL - Hemoglobin <10.0 g/dL - Absolute neutrophil count <2000/mm3 - Lymphocytes <800/mm3 - Platelet count <100,000/mm3 - AST (SGOT) or ALT (SGPT) =2.5 x institutional upper limit of normal - Serum calcium >11.5 mg/dl - International Normalized Ratio of Prothrombin Time (INR) >1.2 - FEV1 <60% predicted or FVC <60% predicted by spirometry (both are to be measured) - Existing or history of brain metastases - History of allergic reactions to compounds of similar chemical or biologic composition to the Study Agent rhLF - Active ischemic heart disease, symptomatic congestive heart failure - Serious active infection - Psychiatric illness/social situations that would limit compliance with study requirements - Autoimmune diseases (e.g., systemic lupus erythematosus, multiple sclerosis or ankylosing spondylitis) - Other malignancies, except non-melanoma skin cancer, within 5 years of study entry - Radiotherapy within 4 weeks prior to study treatment start - Corticosteroid therapy within 4 weeks prior to treatment start, with the exception of inhaled or topical steroids - Chemotherapy/Immunotherapy (e.g., IL-2, INFa, tumor vaccine) within 4 weeks prior to study treatment start - Known HIV positive - Receipt of any investigational medication within 30 days prior to participation in the study - Pregnant or lactating patients, or fertile female patients with a positive pregnancy test (serum ß-human chorionic gonadotropin [ß-HCG] at Screening and on Day 1 prior to the first dose), or fertile female patients unwilling to use adequate contraception prior to study entry, during treatment and 30 days after completion of treatment - Sexually active male patients unwilling to practice contraception while participating on this study and up to 30 days after completion of treatment - Unable to take liquid medication by mouth or feeding tube |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | The University of Chicago Medical Center | Chicago | Illinois |
United States | Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio |
United States | M.D. Anderson Cancer Center | Houston | Texas |
United States | VA Medical Center/Baylor College of Medicine | Houston | Texas |
United States | University of California | Los Angeles | California |
United States | Stanford University School of Medicine | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Agennix |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Best Overall Response rate using RECIST criteria | |||
Primary | 14-WeekProgression-Free Survival (PFS) rate | |||
Secondary | 4 month and 8 month Progression-Free Survival (PFS) rates | |||
Secondary | Median progression-free survival | |||
Secondary | Median Overall Survival (OS) and 1-year OS rate | |||
Secondary | Toxicity |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02248389 -
Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses
|
Phase 1 | |
Completed |
NCT03900364 -
a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A | |
Completed |
NCT00158782 -
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
|
Phase 1 | |
Completed |
NCT03109015 -
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
|
Phase 2 | |
Completed |
NCT00363194 -
A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
|
Phase 1 | |
Completed |
NCT01012011 -
Regulatory Post Marketing Surveillance Study on Nexavar®
|
N/A | |
Completed |
NCT00842790 -
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging
|
N/A | |
Completed |
NCT00529802 -
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
|
Phase 2 | |
Completed |
NCT00338884 -
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
|
Phase 2 | |
Completed |
NCT00387764 -
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
|
Phase 3 | |
Completed |
NCT00356460 -
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
|
Phase 1 | |
Completed |
NCT00043368 -
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
|
Phase 2 | |
Completed |
NCT00079612 -
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04489771 -
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
|
Phase 2 | |
Completed |
NCT00516672 -
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT05104905 -
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT03685591 -
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT03111901 -
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
Completed |
NCT02917772 -
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
|
Phase 2 |